Product
Ad26.ZEBOV, MVA-BN-Filo
1 clinical trial
12 indications
Indication
Virus DiseasesIndication
Hemorrhagic FeverIndication
EbolaIndication
InfectionsIndication
Viral Hemorrhagic FeversIndication
ViralIndication
RNA Virus InfectionsIndication
Filoviridae infectionsIndication
Mononegavirales InfectionsIndication
VaccinesIndication
Immunologic FactorsIndication
PharmacodynamicsClinical trial
A Phase 2, Open-label, Study to Evaluate the Safety and Immunogenicity of a Heterologous 2-dose Vaccination Regimen Using Ad26.ZEBOV, MVA-BN-Filo in Adults and Children Originally Enrolled in the Control Arm of the EBOVAC-Salone StudyStatus: Active (not recruiting), Estimated PCD: 2023-12-31